Table 1.
FIV INa | HIV INa | CHI1019 (8)b | L-870,810 (9)b |
D57 | D64 | X | X |
C58 | C65 | X | X |
T59 | T66 | X | X |
H60 | H67 | X | X |
E85 | E92 | X | X |
T86 | T93 | X | |
D109 | D116 | X | X |
N110 | N117 | X | X |
G111 | G118 | X | X |
P112 | S119 | X | |
N113 | N120 | X | X |
F114 | F121 | X | X |
E145 | E152 | X | X |
N147 | N155 | X | X |
K152 | K159 | X | |
C19 | C19 | X | X |
A20 | A20 | X | X |
a FIV integrase (IN) residues in close contact with the ligands (5.0 Å cutoff) and equivalent residues in HIV-1 IN. Ligands are numbered as in Fig. 4. The active site residues are shown in bold; HIV-1 residues associated with resistance to IN strand transfer inhibitors are in italics; C19 is a DNA nucleotide base, while A20 is the terminal nucleotide of the 3'- end of 3'-processed viral DNA. Numbering of nucleotides corresponds to that adopted in the crystal structure of transposable DNA bound to Tn5 transposase that was used in the present study to model the FIV proviral DNA. b Residues that show close contacts or hydrogen bond interactions with the corresponding ligand are highlighted by a cross. The pose with the highest GOLD score for each compound was considered as the best docking solution.